"Each human cell already has all of the tools required to build these biocomputers on its own", stated Harvard's Yaakov (Kobi) Benenson, a Bauer Fellow in the Faculty of Arts and Sciences' Center for Systems Biology. "All that must be provided is a genetic blueprint of the machine and our own biology will do the rest. Your cells will literally build these biocomputers for you."
Evaluating Boolean logic equations inside cells, these molecular automata will detect anything from the presence of a mutated gene to the activity of genes within the cell. The biocomputers' "input" is RNA, proteins, and chemicals found in the cytoplasm; "output" molecules indicating the presence of the telltale signals are easily discernable with basic laboratory equipment.
"Currently we have no tools for reading cellular signals", Yaakov Benenson stated. "These biocomputers can translate complex cellular signatures, such as activities of multiple genes, into a readily observed output. They can even be programmed to automatically translate that output into a concrete action, meaning they could either be used to label a cell for a clinician to treat or they could trigger therapeutic action themselves."
Yaakov Benenson and his colleagues demonstrate in their Nature Biotechnology paper that biocomputers can work in human kidney cells in culture. Research into the system's ability to monitor and interact with intracellular cues such as mutations and abnormal gene levels is still in progress.
Yaakov Benenson and colleagues including Ron Weiss, associate professor of electrical engineering at Princeton, have also developed a conceptual framework by which various phenotypes could be represented logically.
A biocomputer's calculations, while mathematically simple, could allow researchers to build biosensors or medicine delivery systems capable of singling out very specific types or groups of cells in the human body. Molecular automata could allow doctors to specifically target only cancerous or diseased cells via a sophisticated integration of intracellular disease signals, leaving healthy cells completely unaffected.
Yaakov Benenson and Ron Weiss worked in collaboration with undergraduate Keller Rinaudo, postdoctoral researcher Leonidas Bleris, and summer intern Rohan Maddamsetti, all at Harvard, and with Sairam Subramanian, a graduate student at Princeton. Their research is supported by Harvard University and a centre grant from the National Institute of General Medical Sciences.